{"id":100694,"date":"2025-07-29T00:22:21","date_gmt":"2025-07-29T00:22:21","guid":{"rendered":"https:\/\/www.europesays.com\/us\/100694\/"},"modified":"2025-07-29T00:22:21","modified_gmt":"2025-07-29T00:22:21","slug":"revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/100694\/","title":{"rendered":"Revvity Slashes Outlook As China Policy Deals Diagnostics Blow"},"content":{"rendered":"\n

Revvity Inc.<\/strong>\u00a0(NYSE:RVTY<\/a>) stock is trading lower on Monday following the life science tools maker\u2019s second-quarter 2025 <\/a>earnings report, which also included a trimmed profit forecast for 2025.<\/p>\n

The Massachusetts-based company announced second-quarter sales of $720.28 million, an increase from $691.69 million reported a year ago, surpassing the consensus estimate of $710.71 million<\/a>.<\/p>\n

Delving into the financials, the company\u2019s adjusted earnings for the second quarter were $1.18, exceeding the consensus of $1.14. However, adjusted operating income decreased to $192 million from $199 million in the same period last year, and the adjusted operating profit margin also saw a decline to 26.6% compared to 28.8% a year ago.<\/p>\n

Also Read: Why Thermo Fischer Stock Is Rising Wednesday<\/a><\/strong><\/p>\n

The company’s life sciences segment\u00a0saw\u00a0revenue increase by 5% (+4% organically) to $366 million, led by approximately 30% growth in the Signals Software franchise.<\/p>\n

Diagnostics sales increased 3% year-over-year to $354 million, and organic diagnostics revenue increased 2%, in line with expectations, as immunodiagnostics franchise faced more difficult multiyear comparisons, limiting its growth to the low single digits this past quarter.<\/p>\n

Revvity lowered<\/a> its fiscal year 2025 adjusted earnings from $4.90-$5.00\u00a0per share to\u00a0$4.85-$4.95\u00a0per share compared to the consensus of $4.93<\/a>.<\/p>\n

The company raised its 2025 sales guidance from $2.83 billion-$2.87 billion to $2.84 billion-$2.88 billion, versus the consensus of $2.85 billion.<\/p>\n

View more earnings on RVTY<\/a><\/p>\n

Revvity expects 2025 full-year organic growth to be in the 2% to 4% range, down 1% from the prior outlook<\/a>, with reported growth of 3%- 5%.<\/p>\n

During the investor earnings call, Prahlad Singh<\/strong>, Revvity\u2019s CEO, president, and director, acknowledged the persistent macroeconomic and market challenges. \u201cThe dynamic macro and market environment we experienced during the first quarter of the year continued through the second quarter and at this point, does not yet appear to be settling down as we enter the second half of the year,\u201d Singh stated.<\/p>\n

A significant headwind identified by the company is a recent policy change in China concerning hospital laboratory reimbursement rules, specifically the implementation of Diagnosis-Related Groups (DRG).<\/p>\n

This expanded policy shift is impacting the size of diagnostic panels ordered by physicians in China, initially leading to a reduction in overall volumes for some of Revvity\u2019s multiplex products.<\/p>\n

While this may eventually drive an increase in demand for more expensive single-plex tests, which Revvity also offers, the immediate effect is a \u201cfairly meaningful pullback\u201d in the company\u2019s immunodiagnostics business in China.<\/p>\n

Singh elaborated on the impact, noting that the immunodiagnostics business in China, which accounts for approximately 6% of Revvity\u2019s total revenue, is now projected to experience a high-teen percentage decline for the full year. This revised forecast for the critical China market is the primary driver behind Revvity\u2019s adjusted overall company outlook.<\/p>\n

Price Action:<\/strong> Revvity stock is trading lower by 9.98% to $93.32 at last check Monday.<\/p>\n

Read Next:<\/strong><\/p>\n

Photo via Shutterstock<\/p>\n

Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights<\/strong><\/a> that can set you ahead in today’s competitive market.<\/p>\n

Get the latest stock analysis from Benzinga?<\/p>\n

This article Revvity Slashes Outlook As China Policy Deals Diagnostics Blow<\/a> originally appeared on Benzinga.com<\/a><\/p>\n

\u00a9 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"Revvity Inc.\u00a0(NYSE:RVTY) stock is trading lower on Monday following the life science tools maker\u2019s second-quarter 2025 earnings report,…\n","protected":false},"author":3,"featured_media":100695,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[64,638,55966,65488,79,65605,67,132,68],"class_list":{"0":"post-100694","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-economy","8":"tag-business","9":"tag-company","10":"tag-consensus-estimate","11":"tag-diagnostics","12":"tag-economy","13":"tag-revvity","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114933671103250062","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/100694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=100694"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/100694\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/100695"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=100694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=100694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=100694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}